Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study.

Area of Science:

• Pediatric Oncology
• Cancer Research
• Sarcoma Treatment

Background:

• Parameningeal (PM) rhabdomyosarcoma (RMS) is associated with poor prognosis.
• Previous studies indicate unfavorable outcomes for PM RMS.
• Risk stratification is crucial for managing PM RMS.

Purpose of the Study:

• To describe treatment and outcomes for pediatric patients with PM RMS.
• To investigate the prognostic value of risk factors in PM RMS.
• To evaluate the effectiveness of risk-adapted, multi-modal therapy in PM RMS.

Main Methods:

• Patients with PM RMS were enrolled in the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study.
• Treatment involved risk-adapted, multi-modal therapeutic approaches.
• PM site was scored by originating site and highest risk extension.

Main Results:

• 381 patients with PM RMS were included in the study.
• Radiotherapy was administered to 359 patients (77 with surgery).
• Five-year event-free survival was 60%, and overall survival was 65%.

Conclusions:

• Outcomes for PM RMS patients have not improved compared to historical data.
• Rigorous radiotherapy application (94%) did not enhance survival.
• Meningeal involvement, PM site, and age at diagnosis are significant prognostic factors.